Loss of MAP3K1 expression activates the PI3K/AKT/mTOR pathway and desensitizes the tumor to PI3K inhibition (Avivar‐Valderas et al, 2018), thus mutation status of this gene may affect efficacy of PI3K‐targeting drugs. The gene discussed is PIK3CA; the disease is neoplasm.